Redeye embraces the strong gross margin of 84% vs REe of 80% in the quarter, and we judge the slight deviation in sales and OPEX compared to our estimates as relatively insignificant. We embrace the company’s efforts in setting up its organization for a future US launch through its CLIA lab and reiterate our SEK120 base case.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/